Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006

Ries

DeVita, 2011

Coleman, 2001, Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treat Rev, 27, 165, 10.1053/ctrv.2000.0210

Coleman, 2004, Bisphosphonates: clinical experience, Oncologist, 9, 14, 10.1634/theoncologist.9-90004-14

Vogel, 2004, Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy, Oncologist, 9, 687, 10.1634/theoncologist.9-6-687

Weinfurt, 2005, The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, Ann Oncol, 16, 579, 10.1093/annonc/mdi122

Delea, 2006, Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer, J Thorac Oncol, 1, 571, 10.1016/S1556-0864(15)30361-0

Hirsh, 2008, Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity, J Thorac Oncol, 3, 228, 10.1097/JTO.0b013e3181651c0e

Roodman, 2004, Mechanisms of bone metastasis, N Engl J Med, 350, 1655, 10.1056/NEJMra030831

Hofbauer, 2001, Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases, Cancer, 92, 460, 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D

Selvaggi, 2005, Management of bone metastases in cancer: a review, Crit Rev Oncol Hematol, 56, 365, 10.1016/j.critrevonc.2005.03.011

Coleman, 2005, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid, J Clin Oncol, 23, 4925, 10.1200/JCO.2005.06.091

Brown, 2005, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors, J Natl Cancer Inst, 97, 59, 10.1093/jnci/dji002

Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304

Kitazawa, 2002, RANK ligand is a prerequisite for cancer-associated osteolytic lesions, J Pathol, 198, 228, 10.1002/path.1199

Mundy, 2002, Metastasis to bone: causes, consequences and therapeutic opportunities, Nat Rev Cancer, 2, 584, 10.1038/nrc867

Feeley, 2006, Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration, J Bone Miner Res, 21, 1571, 10.1359/jbmr.060706

Miller R, Jones J, Roudier M, et al. The RANKL inhibitor OPG-Fc, either alone or in combination with docetaxel, blocks lung cancer-induced osteolytic lesions and reduces skeletal tumor burden in a murine model of non-small cell lung cancer in bone. Presented at the 9th International Conference on Cancer-Induced Bone Disease. October 2009 Arlington, VA,:28–31

Miller, 2008, RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis, Mol Cancer Ther, 7, 2160, 10.1158/1535-7163.MCT-08-0046

Gonzalez-Suarez, 2010, RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis, Nature, 468, 103, 10.1038/nature09495

Chen, 2011, RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation, J Cell Biochem, 112, 933, 10.1002/jcb.23009

Jones, 2006, Regulation of cancer cell migration and bone metastasis by RANKL, Nature, 440, 692, 10.1038/nature04524

Tan, 2011, Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling, Nature, 470, 548, 10.1038/nature09707

Rosen, 2003, Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, J Clin Oncol, 21, 3150, 10.1200/JCO.2003.04.105

Rosen, 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial, Cancer, 100, 2613, 10.1002/cncr.20308

Hirsh, 2004, Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications, Clin Lung Cancer, 6, 170, 10.3816/CLC.2004.n.030